Published in British Journal of Haematology (2025)
Collaborator: Sanofi
Authors: Nichola Cooper, Caroline Kruse, Sharon Deneen Morgan, Julie Laurent, Marleni Arvelo-
Saillant, Jean-Pascal Roussy, Matias Cordoba, Imene Gouia, Lisa-Anne Schmitt, Erin Reineke, Terry
Gernsheimer
Immune thrombocytopenia (ITP) is a chronic disease with primary therapeutic goals of platelet
count recovery to safe levels to minimize active/future bleeding, alongside easing additional
symptoms negatively impacting overall patient well-being with consequent improvement in
physical fatigue/energy levels, daily/work-related activities and social/emotional health.
Documentation of this rare disease is important for evaluating real-world experiences in treatment
satisfaction, expectations and unmet needs in disease management.
This study examined patient experiences and preferences, treatment satisfaction and expectations
and unmet patient needs related to disease management and control based on the outcomes of a
survey conducted in adults with ITP.
